BELBUCA® is indicated for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.

BUNAVAIL® is indicated for the treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction treatment Act.

* ONSOLIS® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

ONSOLIS® is licensed in the U.S. to Collegium Pharmaceutical. Outside the U.S., ONSOLIS is licensed to Meda, with the exception of Taiwan, where it is licensed to TTY Biopharm.